LUCD Share Price Performance
US$1.00
0.21 (27.49%)
73.7% undervalued intrinsic discount
US$3.79
Fair Value
Price US$1.00
AnalystConsensusTarget US$3.79
Fair ValueUS$3.79
Share PriceUS$1.00
73.7% undervalued intrinsic discount
LUCD Community Narratives
AN
Fair Value US$3.79 74.1% undervalued intrinsic discount
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Recent LUCD News & Updates
No updates
Lucid Diagnostics Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 13, 2025
- Earnings per share (EPS)
- -0.66
- Gross Margin
- -67.60%
- Net Profit Margin
- -1,699.86%
- Debt/Equity Ratio
- -610.0%
Lucid Diagnostics Inc. Competitors
About LUCD
- Founded
- 2018
- Employees
- 72
- CEO
- WebsiteView website
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading